Evidence map›Paper›PMID 26045047›Full record

ArticleCell death and differentiation2015

NIK promotes tissue destruction independently of the alternative NF-κB pathway through TNFR1/RIP1-induced apoptosis.

L Boutaffala, M J M Bertrand, C Remouchamps, G Seleznik, F Reisinger, M Janas, C Bénézech, M T Fernandes, S Marchetti, F Mair and 10 more

Open access · bronzeAbstract read
In one paragraph

Article in Cell death and differentiation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Lymphotoxin-driven cancer cell eradication by tumoricidal CD8bioRxiv : the preprint server for biology · 2025
    Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. An epithelialProceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 5 countries.

L BoutaffalaLaboratory of Molecular Immunology and Signal Transduction, GIGA-Research, University of Liège, Liège, Belgium.
M J M BertrandThe Inflammation Research Center IRC, VIB, DMBR, Ghent University, Ghent, Belgium.
C RemouchampsLaboratory of Molecular Immunology and Signal Transduction, GIGA-Research, University of Liège, Liège, Belgium.
G SeleznikInstitute of Neuropathology, University Hospital Zürich, Zürich, Switzerland.
F ReisingerInstitute of Virology, Munich, Germany.
M JanasInstitute of Molecular Immunology and Technische Universität München (TUM)/Helmholtz Zentrum München (HMGU), Munich, Germany.
C BénézechSchool of Immunity and Infection, IBR-MRC, Centre for Immune Regulation, University of Birmingham, Birmingham, UK.
M T FernandesLaboratory of Molecular Immunology and Signal Transduction, GIGA-Research, University of Liège, Liège, Belgium.
S MarchettiINSERM U1065, Centre Méditéranéen de Médecine Moléculaire, Nice, France.
F MairInstitute of Experimental Immunology, University of Zurich, Zürich, Switzerland.
C GaneffLaboratory of Molecular Immunology and Signal Transduction, GIGA-Research, University of Liège, Liège, Belgium.
A HupalowskaLaboratory of Molecular Immunology and Signal Transduction, GIGA-Research, University of Liège, Liège, Belgium.
J-E RicciINSERM U1065, Centre Méditéranéen de Médecine Moléculaire, Nice, France.
B BecherInstitute of Experimental Immunology, University of Zurich, Zürich, Switzerland.
J PietteLaboratory of Virology, GIGA-Research, University of Liège, Liège, Belgium.
P KnolleInstitute of Molecular Immunology and Technische Universität München (TUM)/Helmholtz Zentrum München (HMGU), Munich, Germany.
J CaamanoSchool of Immunity and Infection, IBR-MRC, Centre for Immune Regulation, University of Birmingham, Birmingham, UK.ORCID http://orcid.org/0000-0003-3530-7056
P VandenabeeleThe Inflammation Research Center IRC, VIB, DMBR, Ghent University, Ghent, Belgium.
M HeikenwalderInstitute of Virology, Munich, Germany.
E DejardinLaboratory of Molecular Immunology and Signal Transduction, GIGA-Research, University of Liège, Liège, Belgium.
University of Liège · BEGhent University · BEHelmholtz Zentrum München · DEInserm · FRUniversity of Birmingham · GBUniversity of Zurich · CHGerman Cancer Research Center · DEUniversity Hospital of Zurich · CH

Funding

Biotechnology and Biological Sciences Research Council BB/K009400/1
6 · The paper itself

Abstract

NF-κB-inducing kinase (NIK) is well-known for its role in promoting p100/NF-κB2 processing into p52, a process defined as the alternative, or non-canonical, NF-κB pathway. Here we reveal an unexpected new role of NIK in TNFR1-mediated RIP1-dependent apoptosis, a consequence of TNFR1 activation observed in c-IAP1/2-depleted conditions. We show that NIK stabilization, obtained by activation of the non-death TNFRs Fn14 or LTβR, is required for TNFα-mediated apoptosis. These apoptotic stimuli trigger the depletion of c-IAP1/2, the phosphorylation of RIP1 and the RIP1 kinase-dependent assembly of the RIP1/FADD/caspase-8 complex. In the absence of NIK, the phosphorylation of RIP1 and the formation of RIP1/FADD/caspase-8 complex are compromised while c-IAP1/2 depletion is unaffected. In vitro kinase assays revealed that recombinant RIP1 is a bona fide substrate of NIK. In vivo, we demonstrated the requirement of NIK pro-death function, but not the processing of its substrate p100 into p52, in a mouse model of TNFR1/LTβR-induced thymus involution. In addition, we also highlight a role for NIK in hepatocyte apoptosis in a mouse model of virus-induced TNFR1/RIP1-dependent liver damage. We conclude that NIK not only contributes to lymphoid organogenesis, inflammation and cell survival but also to TNFR1/RIP1-dependent cell death independently of the alternative NF-κB pathway.

Indexed as

AnimalsApoptosisCaspase 8Cell LineFas-Associated Death Domain ProteinGTPase-Activating ProteinsHEK293 CellsHumansInhibitor of Apoptosis ProteinsLiverLymphotoxin beta ReceptorMiceMice, Inbred C57BLMice, KnockoutNF-kappa BNF-kappaB-Inducing KinaseCaspase 8Fadd protein, mouseFas-Associated Death Domain ProteinGTPase-Activating ProteinsInhibitor of Apoptosis ProteinsLymphotoxin beta ReceptorNF-kappa BNF-kappaB-Inducing KinaseProtein Serine-Threonine KinasesRalbp1 protein, mouseReceptors, Tumor Necrosis Factor, Type ITumor Necrosis Factor-alpha

Identifiers

PMID26045047
PMCPMC4816116
OpenAlexW1842227014

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.